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Posttranslational modification of proteinswith polyu-
biquitin occurs in diverse signaling pathways and is
tightly regulated to ensure cellular homeostasis.
Studies employing ubiquitin mutants suggest that
the fate of polyubiquitinated proteins is determined
by which lysine within ubiquitin is linked to the C ter-
minus of an adjacent ubiquitin. We have developed
linkage-specific antibodies that recognize polyubi-
quitin chains joined through lysine 63 (K63) or 48
(K48). A cocrystal structure of an anti-K63 linkage
Fab bound to K63-linked diubiquitin provides insight
into the molecular basis for specificity. We use these
antibodies to demonstrate that RIP1, which is essen-
tial for tumor necrosis factor-induced NF-kB activa-
tion, and IRAK1, which participates in signaling by
interleukin-1b and Toll-like receptors, both undergo
polyubiquitin editing in stimulated cells. Both kinase
adaptors initially acquire K63-linked polyubiquitin,
while at later times K48-linked polyubiquitin targets
them for proteasomal degradation. Polyubiquitin
editing may therefore be a general mechanism for
attenuating innate immune signaling.
INTRODUCTION
Ubiquitination is a reversible, ATP-dependent posttranslational
modification in which the C-terminal glycine of ubiquitin is cova-
lently linked through an isopeptide bond to the side chain of a ly-
sine or, less commonly, the amino terminus of a target protein.668 Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc.Three classes of enzymes are required: the ubiquitin-activating
E1, an ubiquitin-conjugating E2, and an ubiquitin ligase E3. The
E3s select the substrate to be modified. A polyubiquitin chain
is formed when one of the seven lysine side chains within ubiq-
uitin is linked to the C-terminal glycine of another ubiquitin. The
best characterized linkages to date utilize ubiquitin K48 and
K63. K48-linked polyubiquitin predominantly, but not exclu-
sively, targets proteins for proteasomal degradation, whereas
K63-linked polyubiquitin more often regulates protein function,
subcellular localization, or protein-protein interactions. Ubiquiti-
nation is reversible due to deubiquitinating enzymes (DUBs) that
can cleave ubiquitin from modified proteins (Hershko and
Ciechanover, 1998).
Identification of polyubiquitin chain linkages on modified pro-
teins has relied largely on mass spectrometry (Kirkpatrick et al.,
2006) and/or the use of mutant ubiquitins with one or more
lysines mutated to arginine (Ea et al., 2006; Finley et al., 1994;
Spence et al., 1995; Wang et al., 2001; Wertz et al., 2004).
Both approaches have their disadvantages. Mass spectrometry
is labor intensive, requires sophisticated instrumentation, and
has limited sensitivity when interrogating rapid changes in the
ubiquitination status of endogenous proteins. Overexpressing
mutant ubiquitins in cells or using mutant ubiquitins in vitro
may not recapitulate accurately modifications that involve wild-
type, endogenous ubiquitin. We have addressed this barrier to
progress by developing linkage-specific antibodies with utility
in a broad range of applications including immunoprecipitation
(IP), immunofluorescence, immunohistochemistry, and western
blotting. Given that ubiquitination is emerging as a critical regu-
lator of a variety of cellular processes including, but not limited
to, cell-cycle progression, the DNA-damage response, activa-
tion of transcription by NF-kB, and regulation of cell survival
(Hershko and Ciechanover, 1998), these reagents hold the
same potential as antibodies specific for phosphorylated amino
acids in revealing the rapid changes in posttranslational modifi-
cations that accompany signaling.
To illustrate the usefulness of these linkage-specific anti-
bodies, we have used them to examine polyubiquitin editing
during signaling by tumor necrosis factor receptor 1 (TNFR1).
The kinase adaptor RIP1, for example, is essential for activation
of the transcription factor NF-kB following stimulation of TNFR1.
RIP1 is recruited to TNFR1 via the adaptor TRADD and must be
polyubiquitinated for interaction with NEMO/IKKg, the regulatory
subunit of the inhibitor of kB kinase (IKK), and for recruitment of
the kinase TAK1. Activated IKK phosphorylates IkB, which is
subsequently ubiquitinated and degraded by the proteasome.
NF-kB transcription factors bound to IkB are thereby released
and are able to translocate into the nucleus (Hayden and Ghosh,
2008). RIP1 recruited to TNFR1 likely bears K63-linked polyubi-
quitin, whichmay be assembled by the E3 TRAF2 (Ea et al., 2006;
Lee et al., 2004b; Wertz et al., 2004). A20, which is a negative
regulator of TNF-induced NF-kB signaling, functions as a DUB
toward RIP1 and, in so doing, disassembles the scaffolding nec-
essary for the recruitment of NEMO and TAK1. Additionally, A20
can function as an E3 ligase and add K48-linked polyubiquitin to
RIP1 to target it for proteasomal degradation (Wertz et al., 2004).
Using our linkage-specific polyubiquitin antibodies, we have
confirmed that RIP1 undergoes polyubiquitin editing and show
that chain switching is a more general mechanism for downregu-
lating signaling. We find that IRAK1, a proximal signaling compo-
nent of the interleukin-1 receptor (IL-1R) and certain Toll-like
receptors (TLRs), also undergoes polyubiquitin editing following
receptor engagement.
RESULTS
Generation of Polyubiquitin Linkage-Specific Antibodies
We took a phage display approach to engineer antibodies spe-
cific for K48- or K63-linked polyubiquitin. A minimal diversity,
bivalent Fab antibody fragment phage display library (Fellouse
et al., 2007; library D) was panned against ubiquitin chains of
either the K63 or K48 linkage (Figure S1A available online). After
four rounds of selection, with later rounds including counterse-
lection against monoubiquitin or polyubiquitin of the other
linkage, specific binders were identified by an enzyme-linked
immunosorbent assay. Twelve clones from each sort were
expressed in E. coli as soluble Fabs, purified, and tested by sur-
face plasmon resonance (SPR) for binding to K48- and K63-
linked polyubiquitin. The highest affinity, most specific clones
were then converted to monovalent format and used as tem-
plates for second generation libraries with additional sequence
diversity engineered into the heavy chain complementarity-de-
termining regions (CDRs) H1, H2, and H3. K48 linkage-selected
clones, for instance, had high sequence diversity in CDR H3, so
the effect of further diversity in CDR H3 was explored. The K63
linkage-selected clones, by contrast, showed little diversity in
CDR H3, so the focus of additional libraries was on optimization
of CDRs H1 and H2. Clone Apu2.07 was the highest affinity anti-
K48 linkage Fab isolated from a second generation library, with
a binding constant of 1.2 nM for K48-linked diubiquitin and no
detectable binding to K63-linked diubiquitin (Table 1). Apu2.16was the highest affinity, most specific anti-K63 linkage Fab
with a binding constant of 92 nM for K63-linked diubiquitin and
42 mM for K48-linked diubiquitin. Notably, Apu2.16 and
Apu2.07 did not compete for binding to K48-linked diubiquitin
(data not shown). Neither Fab demonstrated any detectable
binding to monoubiquitin.
Structural Insights into Fab Recognition of K63-Linked
Diubiquitin
To understand the basis of Apu2.16 specificity, the Fab fragment
was crystallized in complex with K63-linked diubiquitin. The
crystal structure was solved to 2.7 A˚ (Protein Data Bank [PDB]
code 3DVN), and it shows that Apu2.16 recognizes the context
of the K63 linkage rather than the linkage itself (Figure 1A). The
heart of the recognition motif consists of interactions made by
CDR H3, which contacts diubiquitin on either side of the isopep-
tide linkage. The N-terminal portion of CDR H3 (residues E99,
Y100, and Y101) contacts C-terminal residues (72–74) as well
as Q40 from the acceptor ubiquitin, while the distal part of H3
(residues R102 and Y103) contacts the 50 s loop of the K63 do-
nor ubiquitin. Specifically, Y103 intercalates into a pocket be-
tween the donor ubiquitin 50 s loop and the acceptor G76. The
rest of the interface is largely modular with the Apu2.16 light
chain CDRs L1 and L2 interacting with the surface of the K63 do-
nor ubiquitin, while the other two heavy chain CDRs contact the
acceptor ubiquitin. On the ubiquitin side, the C-terminal residues
of the acceptor ubiquitin prior to the isopeptide linkage (espe-
cially L73 and R74) are in much more intimate contact with the
Fab than the isopeptide linkage itself; these two side chains ac-
count for25% of the total surface area buried by diubiquitin on
complex formation. In contrast, G76 contributes 1% of ubiqui-
tin surface area, and K63 of the donor ubiquitin does not partic-
ipate in the interface at all. In addition to extensive Van der Waals
interactions, R74 also facilitates electrostatic complementarity
to the Fab via a salt bridge to a glutamate side chain (E99)
from the proximal part of CDR H3.
Comparison of K63-linked diubiquitin in the above cocrystal to
a crystal structure of K63-linked diubiquitin alone (PDB code
2JF5) or to either the crystal (PDB code 1TBE) or solution struc-
tures of K48-linked diubiquitin (Cook et al., 1992; Varadan et al.,
2002) demonstrates that the Apu2.16 Fab recognizes a specific
conformation of diubiquitin that is unique to the K63 linkage
(Figure 1B). Moreover, a significant portion of the Fab paratope
is derived from CDRs L2 and H2. Because L2 was not
Table 1. Binding Constants for Linkage-Specific
Anti-Polyubiquitin Fabs
Clone
K48-Linked
Diubiquitin Kd (nM)
K63-Linked
Diubiquitin Kd (nM)
Apu2.07 1.2 NB
Apu2.16 42000 92
Apu3.A8 NB 8.7
Apu3.A12 NB 6.2
Apu3.B3 NB 6.1
Fab antibody fragments were analyzed by surface plasmon resonance.
Due to fast kon and koff rates, only the binding constant (Kd) is reported.
NB indicates no detectable binding.Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc. 669
Figure 1. Structural Analysis of Apu2.16 and Apu3.A8
Anti-K63LinkageFabsBound toK63-LinkedDiubiquitin
(A) The complex between K63-linked diubiquitin (orange) and
the Apu2.16 Fab fragment (heavy chain: green, light chain:
magenta). Heavy chain CDR3 (H3) contacts both ubiquitins
on either side of the isopeptide linkage. H3 side chains within
4.2 A˚ of diubiquitin and ubiquitin side chains within 4.2 A˚ of H3
are shown as sticks. Residuesmentioned in the text are in bold
for ubiquitin and italics for the Fab. K63 in the acceptor ubiq-
uitin is shown as a sphere.
(B) Comparison of K63- (top) and K48-linked (bottom) diubi-
quitin. Lysine donor ubiquitins are light orange and acceptor
ubiquitins are bright orange. K48-linked diubiquitin forms
a more compact shape with the chain extending perpendicu-
lar to the ubiquitin dimer, while the K63-linked diubiquitin chain
will extend in a more elongated manner.
(C) Superposition of Apu2.16 (colored as in A) and Apu3.A8
(heavy chain: light green, light chain: pink) showing the loca-
tion of the two changes in L2 (S52R) and H3 (S52T) introduced
in the affinity maturation process to create Apu3.A8. The
structural differences in L1 in the two Fabs are likely due to
crystal packing. L1 (as well as the N terminus) are in a nonca-
nonical conformation likely due to interactions with L3, which
has sequence and structural differences relative to the phage
library parent sequence (Figure S2).
(D) Charge complementarity between Apu3.A8 (transparent)
and diubiquitin (solid). Electrostatic surfaces were calculated
with PyMol. Regions of positive potential are blue; regions
with negative potential are red. In the Apu3.A8 light chain,
R52 (which is introduced in Apu3.A8) and R66 contribute to
a positive region that is close to a negatively charged region
on the ubiquitin surface, created in part by residues D21,
D58, and E18 from the K63 acceptor ubiquitin.randomized in the first or second generation libraries, Apu2.16
was affinity matured by introducing sequence diversity into para-
tope positions within CDRs L2 and H2. Three affinity-matured
clones, Apu3.A8, Apu3.A12, and Apu3.B3, demonstrated single
digit nanomolar binding to K63-linked diubiquitin and no detect-
able binding to K48-linked diubiquitin (Table 1). Both Apu3.A8
and Apu3.A12 contained a S52R substitution in CDR L2 and a
S52T or S52A substitution in CDR H2, respectively (Figure
S1B). Apu3.B3 contained four amino acid substitutions.
To understand the structural consequences of the improve-
ments in Apu3.A8, we crystallized the Fab fragment in complex
with K63-linked diubiquitin and solved the structure to 2.6 A˚ res-
olution (PDB code 3DVG; Figures 1C and S2). Changes in L2 and
H2, which improved greatly the specificity and utility of this anti-
body, had relatively little impact on the structure of the Fab.
Excluding differences in the conformation of CDR L1 and the
N-terminal strand of the light chain, both of which are attributable
to differences in crystal packing, the structures of the two Fabs
are virtually identical (rmsd 0.80 A˚ on 412 C-a atoms). Surpris-
ingly, neither R52 in L2 nor T52 in H2 is in intimate contact with
the diubiquitin, and neither residue contributes much to the ubiq-
uitin-binding surface on Apu3.A8. Instead the effect of these two
mutations appears to be driven largely by improved electrostatic
compatibility between the surface of the K63 donor ubiquitin and
the light chain (Figure 1D). In particular, R52 in L2 and R66 in the
light chain framework form a positively charged surface patch670 Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc.that complements a negative patch on the surface of the K63
donor ubiquitin.
Western Blotting and Immunoprecipitation using
the Polyubiquitin Linkage-Specific Antibodies
The K48 (Apu2.07) and K63 (Apu2.16, Apu3.A8, Apu3.A12, and
Apu3.B3) linkage-specific Fabs were converted to full-length
human immunoglobulins and tested by western blotting for their
ability to recognize polyubiquitin linkages (Figure 2A and data not
shown). All five antibodies recognized purified polyubiquitin
chains of the appropriate linkage and did not bind to monoubi-
quitin. The K48 and K63 linkage-specific antibodies (Apu2.07
and Apu3.A8) also detected smears in cell lysates (Figure 2B)
derived from human embryonic kidney 293T cells, mouse
embryo fibroblasts, insect cells (Spodoptera frugiperda Sf9 or
Trichoplusia ni cells), or yeast (Saccharomyces cerevisiae or
Schizosaccharomyces pombe). Transient transfection of 293T
cells with the E3 TRAF6 amplified the K63-linked polyubiquitin
signal considerably (Figure 2C), consistent with previous studies
characterizing TRAF6 as a K63 ubiquitin ligase (Deng et al., 2000;
Wang et al., 2001).
We utilized the observation that overexpressed TRAF6 is itself
modified by K63-linked polyubiquitin (Wang et al., 2001) to
assess whether the K63 linkage-specific antibody Apu3.A8
would be useful for immunoprecipitation (Figure 2D). When
TRAF6-containing lysates were denatured with 1% SDS to
dissociate TRAF6 from other ubiquitinated proteins, and immu-
noprecipitations were performed following dilution of the SDS
to as low as 0.05%, no TRAF6 was captured by the K63 link-
age-specific antibodies (data not shown). Immunoprecipitation
of TRAF6 was successful, however, when TRAF6 lysates were
denatured with 6 M urea. Western blot analysis for the 3xHA-
epitope tag on TRAF6 revealed a smear of modified protein
(Figure 2D, lane 2). Treatment of the immunoprecipitatedmaterial
with the promiscuous catalytic domain of the DUB USP2
(USP2CD) collapsed the higher molecular weight bands, confirm-
ing ubiquitination of TRAF6 (Figure 2D, lanes 3–5). Nonspecific
proteolytic activity associated with USP2CD did not remove the
slower migrating species because inhibition of USP2CD DUB ac-
tivitywith the cysteine protease inhibitor N-ethylmaleimide (NEM)
prevented collapse of the smear (Figure 2D, lane 6). A portion of
the TRAF6 immunoprecipitated by the K63 linkage-specific anti-
body appeared, by its migration, to be unmodified TRAF6. We
speculate that a cellular DUB was not inactivated fully upon lysis
Figure 2. Apu2.07 Anti-K48 Linkage and Apu3.A8 Anti-
K63 Linkage Antibodies Western Blot and Immuno-
precipitate
(A) Ubiquitin mixtures containing monoubiquitin plus either
K48- or K63-linked chains between two and seven ubiquitins
in length (1 mg/lane or 1, 0.5, and 0.25 mg/lane where a gradient
is indicated) were blotted with Apu2.07 (right panel) or
Apu3.A8 (middle panel) IgGs. SimplyBlue SafeStain revealed
the composition of the polyubiquitin mixtures (left panel).
(B) Protein extracts from human 293T cells, mouse embryo
fibroblasts (MEF), Sf9 and T.ni insect cells, S. cerevisiae, and
S. pombe (50–175 mg extract/lane) were stained with Sim-
plyBlue SafeStain (left panel) or blotted with Apu3.A8 (middle
panel) or Apu2.07 (right panel). Control lanes contained K48-
or K63-linked tetraubiquitin (0.2 mg).
(C) Overexpression of 33HA epitope-tagged TRAF6
enhanced the high molecular weight smear detected in 293T
cells by Apu3.A8.
(D) Apu3.A8 immunoprecipitated 33HA-tagged TRAF6 from
293T cells.
(E) Apu2.07 immunoprecipitated 33HA-tagged IkBa from
293T cells.
and that this DUB generated the faster-migrating
species of TRAF6 during the immunoprecipitation.
The ability of the K48 linkage-specific antibody to
immunoprecipitate K48-linked polyubiquitinated
proteins was determined using overexpressed
3xHA-tagged IkBa. A smear of IkBa was immuno-
precipitated by the K48 linkage-specific antibody,
which was converted to a faster migrating smear
by USP2CD in a NEM-sensitive manner (Figure 2E).
An isotype control antibody recognizing human
HER2 failed to immunoprecipitate either IkBa or
TRAF6 (Figure 2E and data not shown).
Confirmation of Antibody Linkage
Specificity by Mass Spectrometry
Having established that the K48 and K63 linkage-
specific antibodies could immunoprecipitate polyu-
biquitinated proteins, we sought to confirm their linkage specific-
ity in this application usingmass spectrometry. Polyubiquitinated
proteins were immunoprecipitated from human BJAB cells,
resolved by SDS-PAGE, subjected to in-gel trypsin digestion,
and then analyzed using a variation of the ubiquitin-AQUA
method (Kirkpatrick et al., 2006). Briefly, trypsin digests were
supplemented with isotope-labeled internal standard peptides
representing each polyubiquitin chain linkage and unbranched
ubiquitin, and then the standards plus their corresponding native
analytes were detected in high-resolution precursor ion scans
using narrow range-extracted ion chromatograms. The abun-
dance of each polyubiquitin chain linkage and the total amount
of ubiquitin in the BJAB immunoprecipitates were quantified by
comparing the signal from each digested peptide relative to its
corresponding internal standard. The anti-K48 linkage, anti-K63
linkage (Apu3.A8), and isotype control antibodies immunoprecip-
itated49.1pmol, 2.2pmol, and0.2pmol of total ubiquitin, respec-
tively (Figure 3A). This result was in keeping with the observationCell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc. 671
that K48-linked polyubiquitin was more abundant than K63-
linked polyubiquitin in the input lysate used for the immunopre-
cipitations (Figure 3B). Direct examination of the polyubiquitin
linkages immunoprecipitated by the anti-K48 linkage antibody
revealed 12.7 pmol of K48 –GG signature peptide and measur-
able amounts of the signature peptides for other linkages: 0.1
pmol K63, 1.1 pmol K11, and 2.0 pmol K6 (Figure 3C). Similarly,
polyubiquitin immunoprecipitated by the anti-K63 linkage
antibody did not produce exclusively the K63 –GG signature
peptide; 0.3 pmol K63, 0.18 pmol K48, 0.08 pmol K11, and 0.06
pmol K6 were detected (Figure 3D). Given the strong binding
preferences seen for the antibodies by SPR (Table 1), these
mass spectrometry results suggest that a significant fraction of
ubiquitin-modified cellular substrates (or complexes that resist
dissociation in 6 M urea) exhibit heterogeneous polyubiquitin
chain linkages.
To confirm that the mixed linkages immunoprecipitated from
BJAB cell lysates derived from substrates bearing heteroge-
Figure 3. Mass Spectrometry Confirms the Linkage
Specificity of Apu2.07 and Apu3.A8 in Immuno-
precipitations
(A–D) BJAB cell lysates were immunoprecipitated with
Apu2.07, Apu3.A8, or an isotype control antibody recognizing
HER2. Mass spectrometry was used to determine the total
amount of ubiquitin immunoprecipitated (A) as well as the pol-
yubiquitin linkages in the lysate (B) and immunoprecipitates
(C and D).
(E) MuRF1 autoubiquitination reactions performed in vitro with
WT, K48R, or K63R ubiquitin were immunoprecipitated with
Apu2.07, Apu3.A8, or isotype control. Numbers in parenthe-
ses indicate the relevant lanes and columns in (F)–(I).
(F) Autoubiquitination reactions and immunoprecipitations de-
picted in (E)werewesternblottedwithapan-ubiquitin antibody.
Thehatched red lines indicate theportionof thegel thatwascut
out and subjected to analysis by mass spectrometry.
(G–I) Mass spectrometry was used to determine the polyubi-
quitin linkages in the autoubiquitination reactions and immu-
noprecipitations depicted in (E).
neous polyubiquitin chains, as opposed to nonspe-
cific binding, we tested whether the target linkage
was necessary for immunoprecipitation of the other
linkage types. Mixed linkage polyubiquitin chains
with either the K48 or K63 linkage absent were
generated in vitro using the E3 MuRF1 and the E2
UbcH5c (Kim et al., 2007). The K48 or K63 linkage
was excluded from the MuRF1 autoubiquitination
reactions using mutant ubiquitin that had either
K48 or K63 mutated to arginine (Figure 3E).
By western blotting with a pan ubiquitin antibody,
MuRF1 autoubiquitination reactions produced
high molecular weight smears irrespective of
whether we used wild-type (WT), K48R, or K63R
ubiquitin (Figure 3F, lanes 1, 5, and 9). Ubiquitin-
AQUA analysis of the reaction with WT ubiquitin
revealed three main linkages: K48, K63, and K11
(Figure 3G, lane 1). As expected, reactions per-
formed with K48R ubiquitin lacked K48-linked
chains (Figure 3G, lane 5) and those performed with K63R
ubiquitin lacked K63-linked chains (Figure 3G, lane 9). Both the
anti-K48 and anti-K63 linkage antibodies immunoprecipitated
polyubiquitinated species when MuRF1 was modified with WT
ubiquitin (Figure 3F, lanes 3 and 4), but each antibody failed to
do so if their target linkage was absent (Figure 3F, lanes 7 and
12). An isotype control antibody did not immunoprecipitate ubiq-
uitinated MuRF1 from any of the reactions (Figure 3F, lanes 2, 6,
and 10). Ubiquitin-AQUA analysis of the immunoprecipitated
species from the WT ubiquitin reaction demonstrated the pres-
ence of K48-, K63-, and K11-linked chains regardless of the
antibody used for enrichment (Figure 3H, lane 3 and Figure 3I,
lane 4). As predicted by western blotting (Figure 3F, lanes 7 and
12), K11-linked chains were immunoprecipitated by both the
anti-K48 and anti-K63 linkage antibodies only if their target link-
age was also present (Figures 3H and 3I). These results demon-
strate that the anti-K48 and anti-K63 linkage antibodies retain
their fidelity in the context of immunoprecipitation. Further, they672 Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc.
indicate that alternative linkages immunoprecipitated from cells
by the K48 and K63 linkage-specific antibodies must stem from
individual substrates (or complexes not dissociated by 6 M
urea) bearing both the target linkage and other linkage types.
Whether individual chains contain mixed linkages or whether
substrates carry polyubiquitin chains of different linkages on sep-
arate lysines remains to be determined.
Localization of K48- and K63-linked Polyubiquitin
within Cells
We used the linkage-specific polyubiquitin antibodies to deter-
mine the distribution of K48- and K63-linked polyubiquitin within
cells by indirect immunofluorescence microscopy (Figures 4A
and 4D). Apu2.07 anti-K48 linkage antibody stained both the
nucleus and cytoplasm of HeLa cells, but what appeared to
be nucleoli within the nucleus were labeled less intensely
(Figure 4A). This pattern of staining coincided almost com-
pletely with proteasomes labeled with a polyclonal antibody
recognizing the core 20S subunits (Figures 4B and 4C), which
is consistent with the notion that K48-linked polyubiquitin
generally targets proteins for proteasomal degradation. Inter-
estingly, K48-linked polyubiquitin, but not proteasomes, was
detected at the midbody during mitosis. Apu3.A8 anti-K63 link-
age antibody had a very different staining pattern, labeling cyto-
plasmic speckles that varied both in number and size between
individual cells (Figure 4D). We did not detect colocalization of
K63-linked polyubiquitin with proteasomes in these speckles
Figure 4. Immunofluorescent and Immunohistochemical
Staining of K48- and K63-Linked Polyubiquitin
(A–F) HeLa cells were stained with Apu2.07 (A), Apu3.A8 (D), and
a polyclonal antibody recognizing 20S proteasome subunits
(B and E). The arrow indicates mid-body staining. In the merged
images (C and F), yellow staining indicates potential colocalization
and blue staining corresponds to DAPI-labeled nuclei. Bars,
50 mm.
(G–L) HeLa cells harvested 1 hr after UV irradiation (50 J/m2) were
stained with Apu2.07 (G–I) or Apu3.A8 (J–L). Antibody specificity
was assessed by preincubating the antibodies with either K48-
(H and K) or K63-linked tetraubiquitin (I and L).
(Figures 4E and 4F). Nor did the K63-linked polyubi-
quitin speckles colocalize with Golgi complex and
lysosomal markers (Figure S3). In control experi-
ments, staining by the linkage-specific antibodies
could be competed by synthesized polyubiquitin
only if the chains contained the target linkage (data
not shown). These results indicate that K48- and
K63-linked polyubiquitin can occur in distinct subcel-
lular regions.
We also tested whether the linkage-specific anti-
bodies would be useful for immunohistochemistry
and found that formalin-fixed, paraffin-embedded
sections of HeLa cells also were stained effectively
by the Apu2.07 anti-K48 and Apu3.A8 anti-K63 linkage
antibodies (Figures 4G and 4J). Staining was com-
peted by tetraubiquitin containing the target linkage
but not by tetraubiquitin containing an alternative linkage
(Figures 4H, 4I, 4K, and 4L).
RIP1 Undergoes Polyubiquitin Chain Editing
The utility of the K48 and K63 linkage-specific antibodies in un-
veiling the type of ubiquitination on a specific target protein was
assessed with endogenous RIP1 in HeLa S3 cells treated with
TNF (Figure 5). It has been shown that RIP1 recruited to TNFR1
is polyubiquitinated (Ea et al., 2006; Legler et al., 2003; Wertz
et al., 2004) and, based on in vitro and overexpression studies,
K63-linkedpolyubiquitin onRIP1 supports downstreamsignaling
events resulting in NF-kB activation (Ea et al., 2006). The K63-
linked polyubiquitin eventually is replacedwith K48-linked chains
by A20, which has dual function as a DUB and K48-promoting E3
(Wertz et al., 2004). The A20 gene is a transcriptional target of NF-
kB and thus forms part of a negative feedback loop to terminate
NF-kB signaling (Hayden andGhosh, 2008). Consistent with pre-
vious results (Ea et al., 2006; Legler et al., 2003; Wertz et al.,
2004), a smear of RIP1 was associated with TNFR1 within 5 min
of TNF addition (Figure 5B), and this coincided with degradation
of IkBa (Figure 5A), which served as our readout for activation of
the NF-kB pathway. Modified RIP1 was less abundant at later
time points (Figure 5B), which is consistent with a previous study
showing that RIP1 polyubiquitinated in response to TNF is de-
graded by the proteasome (Legler et al., 2003). Next we immuno-
precipitated TNFR1-containing complexes at different times
after treatment with TNF, dissociated the receptor complexesCell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc. 673
in 6 M urea, and then immunoprecipitated with either the K48 or
K63 linkage-specific polyubiquitin antibodies before blotting for
RIP1. This experiment revealed that TNFR1-associated RIP1
was modified almost entirely by K63-linked chains at 5 min
(Figure 5C). The intensity of the K63-linked polyubiquitin signal
on RIP1 was decreased at 10 min and K48-linked polyubiquitin
was detected, the latter also diminishing at later times presum-
ably asa result of proteasomal degradation ofRIP1. These results
confirm that TNFR1-associated RIP1 undergoes polyubiquitin
editing during TNFR1 signaling.
IRAK1 Undergoes Polyubiquitin Chain Editing
Given that RIP1 is modified sequentially by K63- and then K48-
linked polyubiquitin, the latter being conferred by E3 A20, and
that A20 also is a negative regulator of signaling by certain
TLRs (Boone et al., 2004), we investigated whether other kinase
adaptors recruited to TLRs and the IL-1R might be regulated in
a similar fashion. IRAK1 appeared a good candidate for under-
going polyubiquitin editing because posttranslationally modified
IRAK is recruited rapidly to activated receptor complexes and
subsequently is degraded (Yamin and Miller, 1997). We treated
293 cells stably expressing the IL-1R with IL-1b, and consistent
with the work of Yamin and Miller (1997), western blotting
revealed a smear of modified IRAK1 within 2 min (Figure 6A).
The slower migrating forms of IRAK1 were more abundant at
10 min and could be converted to the unmodified form of
IRAK1 by USP2CD in a NEM-sensitive manner. These results
suggest that the higher molecular weight forms of IRAK1 are
due to ubiquitination. The appearance of ubiquitinated IRAK1
coincided with activation of downstream NF-kB signaling as
evidenced by IkBa degradation (Figure 6B). At different times
after treatment with IL-1b, we also prepared cell lysates in 6 M
urea and then immunoprecipitated with the linkage-specific an-
tibodies prior to western blotting for IRAK1 (Figure 6C). IRAK1
modified with K63-linked polyubiquitin was detected at 5 min
and was maximal by 30–60 min, which mirrored the kinetics of
appearance of the highmolecular weight IRAK1 smear (compare
the upper panels of Figures 6B and 6C). The amount of K48-
linked polyubiquitin evident on IRAK1 peaked at 90–150 min,
Figure 5. Linkage-Specific Polyubiquitin Anti-
bodies Reveal Chain Editing of RIP1 in TNF-
Treated Cells
HeLa cells pretreated with 21 mMMG-132 for 10 min were
stimulated with 100 ng/ml TNF. Western blots show total
RIP1, IkBa, and tubulin levels (A), immunoprecipitated
TNFR1 and associated RIP1 (B), and RIP1 that is associ-
atedwith TNFR1 and is polyubiquitinatedwith K63- (C, up-
per panel) or K48-linked chains (C, lower panel). Complete
proteasome inhibition in cells by MG-132 pretreatment is
not apparent until approximately 45 min post-addition
(Figure S4), so IkBa and RIP1 modified by K48-linked
polyubiquitin can be degraded at the times shown.
which is when the intensity of the total IRAK1
signal began to subside. When cells treated
with IL-1b were not pretreated with proteasome
inhibitor MG-132, this degradation of ubiquiti-
nated IRAK1 was accelerated (Figure S4), consistent with the
K48-linked polyubiquitin targeting IRAK1 for the proteasome.
Thus polyubiquitin editing of IRAK1 in cells treated with IL-1b re-
sembles that of RIP1 in cells treated with TNF, and this process
of chain editing may represent a general mechanism of terminat-
ing downstream signaling events.
DISCUSSION
Our rationale for developing antibodies with the ability to dis-
criminate between polyubiquitin chain linkages is that they rep-
resent the best tools for addressing whether chain linkage is
a major determining factor in the fate of polyubiquitinated pro-
teins. The first indication that different chain linkages might
have unique functions came from the study of yeast mutants in
which either K48 or K63 of ubiquitin was mutated to arginine;
K63-linked polyubiquitin was implicated in DNA repair (Spence
et al., 1995), whereas K48-linked polyubiquitin was important
for protein degradation and for progression through the cell cycle
(Finley et al., 1994). Assessment of polyubiquitin chain linkage on
modified mammalian proteins commonly involves immunopre-
cipitation of the protein from cells overexpressing epitope-
tagged ubiquitin mutants and/or in vitro ubiquitination assays
with the same ubiquitin mutants (for examples, see Ea et al.,
2006; Wang et al., 2001; Wertz et al., 2004). The potential pitfalls
of using ubiquitin mutants are (1) the E2 and/or E3 might be sen-
sitive to lysine mutations at nonlinkage sites, (2) other lysines
might be usedwhen the preferred lysine is absent, and (3) incom-
plete penetration of themutant ubiquitin into the total pool of cel-
lular ubiquitin may limit its ability to interfere dominantly with spe-
cific linkage-mediated events. The impact of epitope tags on
ubiquitin chain assembly also is unclear. Diagnostic antibodies
that recognize specific polyubiquitin chain linkages and can be
used for immunoprecipitation and western blotting therefore
provide the quickest, simplest means of determining polyubiqui-
tin chain linkage.
The use of a minimalist diversity phage display library in
combination with powerful in vitro selection methods was critical
to our success in generating high-affinity, linkage-specific674 Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc.
antibodies to polyubiquitin. Indeed, exhaustive efforts to gener-
ate polyubiquitin linkage-specific antibodies by traditional immu-
nization strategies proved futile, probably reflecting the inability
of the naturally occurring antibody repertoire to recognize
these highly conserved epitopes. The minimalist library was
key because we did not enrich for specific binders using a syn-
thetic library with CDRs based on natural diversity (Lee et al.,
2004a). CDR H3 typically makes the largest contribution to anti-
gen recognition, so the minimalist library provides complex
diversity in CDR H3 to allow selection for specific interactions,
while binary diversity (Ser or Tyr) in the other CDRs minimizes
steric hindrance and enables adaptation to varied surfaces. Of
note, however, initial binders from this library are often low affin-
ity and require affinity optimization. Refinement of the anti-K48
polyubiquitin linkage antibody was accomplished readily by en-
gineering additional diversity into CDR H3 and repeating the se-
lection process. The resulting anti-K48 linkage Fab, Apu2.07,
was of high affinity and specificity. By contrast, the anti-K63 link-
age Fab, Apu2.16, had additional diversity in CDRs H1 and H2
but it required even further affinity maturation. The structure of
Apu2.16 in complex with K63-linked diubiquitin (Figure 1) guided
Figure 6. Linkage-Specific Polyubiquitin Antibodies Reveal Chain
Editing of IRAK1 in IL-1b-Treated Cells
293 cells stably expressing the IL-1 receptor were pretreated with 25 mMMG-
132 for 10 min and then stimulated with 10 ng/ml IL-1b. Western blots show
total IRAK1, IkBa, and tubulin levels (A and B) and IRAK1 that is modified by
K63- (C, upper panel) or K48-linked polyubiquitin (C, lower panel).construction of third generation libraries. By focusing on the
important contacts between K63-linked diubiquitin and CDRs
L2 and H2, we obtained clones that were of sufficient affinity
and specificity for characterization of K63-linked polyubiquitina-
tion in cells.
We focused on the generation of K48 and K63 linkage-specific
polyubiquitin antibodies because these linkages are the best
studied to date (Hershko and Ciechanover, 1998). Mass spec-
trometry, in combination with enrichment strategies to capture
ubiquitinated proteins in yeast (Peng et al., 2003) or in mouse
brain (Bennett et al., 2007), has shown that K48 linkages are
dominant, while K63 and K11 linkages are the next most abun-
dant. K33, K27, and K6 linkages have been detected in yeast
but appear to be present at much lower levels (Peng et al.,
2003). K48 and K63 linkages dominated our BJAB cell lysates
(Figure 3B), but K6 and K11 linkages were detected following en-
richment with either the K48 or K63 linkage-specific antibodies
(Figures 3C and 3D). These alternative linkages did not represent
nonspecific binding of the polyubiquitin antibodies because they
could only be immunoprecipitated from in vitro autoubiquitina-
tion reactions when the target linkage was present (Figures 3H
and 3I). These data could indicate that a significant fraction of
polyubiquitinated substrates within cells bear heterogeneous
chain linkages. Unfortunately, the methodologies used do not
discern whether substrates carry polyubiquitin chains of mixed
linkages or several different chains each of a uniform linkage.
It also is possible that the heterogeneous polyubiquitin chain
linkages stem from coprecipitating proteins that resist dissocia-
tion in 6 M urea.
Polyubiquitin modifications are well described in the signaling
pathways triggered by cytokines TNF and IL-1b, so we used
these systems to demonstrate the power of the linkage-specific
antibodies for interrogating ubiquitin chain editing during signal
transduction in vivo (Figures 5 and 6). Previously, we showed
by coexpressing mutant ubiquitins with all but one lysine mu-
tated to arginine that RIP1 acquires K63-linked polyubiquitin in
the presence of E3 TRAF2 (Wertz et al., 2004). Indeed, TNF-
induced RIP1 polyubiquitination is defective in TRAF2-deficient
MEFs (Lee et al., 2004b). The K63-linked polyubiquitin on over-
expressed RIP1 can be replaced with K48-linked polyubiquitin
by A20 (Wertz et al., 2004). We now demonstrate directly using
our linkage-specific antibodies that endogenous RIP1 recruited
to TNFR1 is modified transiently by K63-linked polyubiquitin as
NF-kB is activated and then is modified by K48-linked polyubi-
quitin (Figures 5C and S5A). The latter modification coincides
with degradation of TNFR1-associated RIP1 (Figure 5B) and
termination of NF-kB signaling.
We also show that endogenous IRAK1 exhibits a similar pat-
tern of polyubiquitination in cells treated with IL-1b (Figures 6
and S5B). IRAK1 is recruited to the IL-1R (and certain TLRs),
where it is phosphorylated and subsequently degraded (Yamin
and Miller, 1997). TRAF6 is reported to assemble K63-linked
polyubiquitin on IRAK1 (Conze et al., 2008) although Pellino pro-
teins have been implicated in IRAK1 ubiquitination also (Ordureau
et al., 2008; Xiao et al., 2008). This polyubiquitination has been
suggested to mediate recruitment of NEMO for NF-kB activation
(Conze et al., 2008; Windheim et al., 2008), although one study of
IRAK1-deficient cells indicated that IRAK1 was dispensable forCell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc. 675
IL-1b-induced NF-kB activation at higher doses of IL-1b (Kana-
karaj et al., 1998), perhaps due to functional redundancy with
IRAK2. Given that IRAK1 and the ubiquitin-dependent kinase
TAK1 are both essential for IL-1b-induced activation of MAP ki-
nases p38 and JNK (Kanakaraj et al., 1998; Thomas et al., 1999;
Sato et al., 2005), K63-linked polyubiquitination of IRAK1 might
also contribute to activation of TAK1. Phosphorylation and poly-
ubiquitination of IRAK1 occur normally in TAK1-deficient cells
treated with IL-1b, consistent with TAK1 acting downstream of
IRAK1 (Sato et al., 2005).
IRAK1 activated by the IL-1R eventually is degraded (Figure 6
and Yamin and Miller, 1997). The reduction in IRAK1 correlates
with modification of IRAK1 by K48-linked polyubiquitin so these
chains likely target IRAK1 for proteasomal degradation. Indeed,
we find that the proteasome inhibitor MG-132 can abrogate
IRAK1 degradation (Figure S4). It remains to be determined
whether a dual function E3/DUB such as A20 is responsible for
the ubiquitin chain switching on IRAK1. Because both RIP1
and IRAK1 undergo chain editing as a means of downregulating
cytokine signaling, it will be interesting to determine whether
other kinases are regulated in this manner.
EXPERIMENTAL PROCEDURES
Phage Display
Phage display libraries were generated and sorted as described (Sidhu et al.,
2000). SPR was done using a BIACORE A100 or 3000. K63- or K48-linked
diubiquitin (50 resonance units; Boston Biochem) were immobilized on
a CM5 chip using an amine coupling protocol. For reference subtraction,
a spot was activated and ethanolamine blocked without immobilizing protein.
Serial dilutions (31.25–500 nM) of Fabs were injected (60 ml total at 30 ml/min).
The chip was regenerated with 15 ml of 10 mM HCl after 10 min. Kinetic and
binding constants were calculated by nonlinear regression analysis. Fab
variable domains were cloned into pRK vectors encoding the heavy chain of
human IgG1 and a human kappa light chain. IgGs were expressed transiently
in 293 or CHO cells and purified on protein A- or protein G-sepharose.
Crystallography
Fab fragments expressed in E. coli were purified with protein G-sepharose
(0.58% acetic acid elution) and then a SP HiTrap column (GE) with 20 mM
MES pH 5.5 and a NaCl gradient. A S-200 column (GE) in 20 mM Tris-HCl
(pH 7.3), 150 mM NaCl also was used for Apu3.A8. K63-linked diubiquitin
was produced according to Pickart andRaasi (2005) and purifiedwith aMonoS
column in a NaCl gradient and 20 mM MES (pH 5.5). Fab-diubiquitin com-
plexes were purified on a Superdex 75 column in 20 mM Tris-HCl (pH 7.3),
150 mM NaCl. Apu2.16 crystals grew in 2 weeks at 18C in sitting drops
from a 1:1 mixture of protein (12.7 mg/ml in 10 mM Tris-HCl pH 8.0, 75 mM
NaCl) and well solution (0.2 M NaCl, 0.1 M Tris pH 8.2, 0.1 M citrate). For cry-
oprotection, well solution contained 18%glucose. Apu3.A8 crystals grew after
2 weeks at 18C in sitting drops from 1:1 mixtures of protein (17 mg/ml in
20 mM Tris-HCl pH 7.3, 150 mM NaCl) and well solution (0.1 M Tris-HCl pH
8.0, 1.6 M LiSO4). For cryoprotection, well solution contained 30% glycerol.
Data were collected at SSRL beamlines 9-2 (Apu2.16 complex) and 7-1
(Apu3.A8) (Table S1) and were processed with HKL. Structures were solved
by molecular replacement using PHASER (CCP4) and refined with REFMAC5
(CCP4). For the Apu2.16 complex, the humanized 4D5 Fab (PDB code 1FVE)
and ubiquitin (PDB code 1UBQ) were used as search models. The Apu3.A8
complex was solved using the refined Apu2.16 complex as a search model.
All figures were made with PyMol (http://www.pymol.org).
Mass Spectrometry
Burkitt lymphoma BJAB cells (>109) were washed in PBS and lysed for 30 min
at room temperature in lysis buffer (20 mM Tris-HCl pH 7.5, 135 mM NaCl,676 Cell 134, 668–678, August 22, 2008 ª2008 Elsevier Inc.1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 10% glycerol) containing 6 M
urea, 2 mM N-ethylmaleimide (NEM), and protease inhibitors (Roche). The
soluble lysate was diluted to 4 M urea with lysis buffer (supplemented with
protease inhibitors, 2 mM NEM, and 1 mM DTT) and precleared with protein
A-sepharose for 1 hr. The lysate was divided into three samples, which re-
ceived either 30 ug of Apu3.A8 IgG, Apu2.07 IgG, or isotype control antibody
Herceptin. Samples were mixed for 2 hr, then centrifuged to remove precipi-
tated material. Further antibody (10 ug) plus protein A-sepharose was added
and the samples were mixed overnight. The sepharose beads were washed
extensively in lysis buffer and once in PBS before elution in reducing SDS
sample buffer. Proteins were alkylated with iodoacetamide and resolved by
SDS-PAGE. Excluding the 25 and 55 kDa regions, the rest of each gel lane
was washed in 25 mM NH4HCO3 in 50:50 acetonitrile:water and dehydrated.
Gel pieces were rehydrated in 25 mMNH4HCO3 containing trypsin (Promega),
incubated overnight at 37C, and then extracted once in 5% acetic acid and
twice in 100% acetonitrile. The peptide digests were spiked with AQUA
peptide standards (1 pmol) and separated on a NanoAcquity UPLC system
(Waters) with a precolumn (5 mm Symmetry C18, 1803 20 mm) and an analyt-
ical column (1.7 mm BEH-130 C18 column 100 3 100 mm, Waters), using a
70 min gradient from 2% to 90% solvent B (solvent A is water + 0.1% formic
acid; solvent B is 100% acetonitrile + 0.1% formic acid) and a total analysis
time of 90 min. Peptides were eluted directly into a nanospray ionization
source with a spray voltage of 2 kV and analyzed using an LTQ XL-Orbitrap
mass spectrometer (ThermoFisher). Precursor ions were analyzed in the
FTMS at 60,000 resolution. Quantitation was performed by comparing peak
areas for the heavy and light versions of each peptide, extracting the ion chro-
matograms at 10 ppm mass accuracy to 4 decimal places.
MuRF1 autoubiquitination reactions were performed according to the
manufacturer (Boston Biochem). For immunoprecipitations, samples were
diluted 100-fold in lysis buffer containing 4 M urea, precleared with protein
A-sepharose, and then incubated overnight with antibody (20 ug) and protein
A-sepharose. Total ubiquitin was blotted with P4D1 antibody (Santa Cruz
Biotechnology). For mass spectrometry, samples were resolved on an Agilent
1100 LC module with a 15 min gradient from 5% to 30% Solvent B and a total
analysis time of 30 min. Ion chromatograms were created by extracting a
window ± 15 ppm from the expected m/z.
Immunoprecipitation, Western Blotting, and Deubiquitination
293T cells were transfected with 33HA-tagged versions of human IkBa or
TRAF6 using Lipofectamine 2000 (Invitrogen). Cells were lysed 36 hr later in
lysis buffer containing 6 M urea, a complete protease inhibitor cocktail, and
2 mM NEM. Immunoprecipitations were as described above except that sam-
ples were diluted with lysis buffer to 0.3 M urea and were performed at 4C.
Beads were washed sequentially in lysis buffer, PBS, and DUB reaction buffer
(40 mM sodium phosphate pH 8, 150 mM NaCl, 2 mM DTT, 10% glycerol).
Where indicated, beads were incubated at 25C with USP2CD (Boston Bio-
chem) ± 5mMNEM. Sf9 and T.ni cells were harvested in lysis buffer containing
protease inhibitors. 293T and C57BL/6 mouse embryo fibroblast lysates also
contained 1 mM DTT, 2 mM NEM, and a PhosSTOP cocktail (Roche). S. cer-
evisiae YRG-2 andS. pombe SP-Q01 cells (Stratagene) grown in YPD and YES
medium, respectively, were extracted in Y-PER (Pierce) supplemented with
5 mM DTT, 2 mM NEM, and 25 mM MG-132 (Calbiochem). Polyubiquitin blot-
ted with Apu2.07 and Apu3.A8 was revealed with peroxidase-conjugated goat
anti-human IgG (Cappel).
HeLa S3 cells were treated with 21 mMMG-132 for 10min prior to addition of
100 ng/ml TNF (Genentech). Cells were lysed at 4C in TNFR1 immunoprecip-
itation buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, and
1 mM EDTA) containing protease and phosphatase inhibitors, 25 mM MG-132,
10 mM NEM, and 50 mM NaF. For immunoprecipitations, the soluble lysate
was precleared with protein A-sepharose for 1 hr and then incubated with
anti-TNFR1 antibody (Genentech) plus protein A-sepharose at 4C for 5 hr.
Beads were washed twice with TNFR1 immunoprecipitation buffer, twice with
TNFR1 immunoprecipitation buffer containing 1 M NaCl, and twice with
TNFR1 immunoprecipitation buffer. Proteins were eluted in lysis buffer con-
taining 6 M urea. For serial immunoprecipitations, samples were diluted
25-fold with lysis buffer containing protease inhibitors, 10 mM NEM, and
0.5 mM DTT, precleared with protein A-sepharose plus Herceptin, and then
incubated with either Apu2.07 or a 1:1 mix of Apu3.A8 and Apu3.B3 pre-
coupled to protein A-sepharose for 2 hr at 4C. Antibodies used for western
blotting recognized RIP1 (BD Biosciences), b-tubulin (ICN Biomedicals), and
IkBa (Cell Signaling Technology).
293 cells stably expressing IL-1R and IL1R-AcP were treated with 25 mM
MG-132 for 10 min prior to addition of 10 ng/ml IL-1b. Cells were lysed in
IRAK immunoprecipitation buffer (20 mMHEPES pH 7.6, 150mMNaCl, 1.5mM
MgCl2, 2 mM EGTA, 10 mM NaF, 2 mM DTT, and 0.5% Triton X-100) contain-
ing 6 M urea. Soluble lysates were diluted 20-fold and incubated with either
Apu2.07 or a 1:1 mix of Apu3.A8 and Apu3.B3 as described above for RIP1.
Immunofluorescence Staining
HeLa cells were fixed with 4% paraformaldehyde in PBS at room temperature
for 20 min, rinsed twice with PBS, and permeabilized with PBS containing
0.1% Triton X-100 for 5 min. Nonspecific binding sites were blocked with Ear-
le’s balanced salt solution containing 10%goat serum, 0.1%Triton X-100, and
0.1% saponin for 1 hr, then cells were labeled overnight at 4C with 1 mg/ml
Apu2.07, 1 mg/ml Apu3.A8, or 5 mg/ml PW8155 anti-proteasome (Biomol Inter-
national). Cells were washed three times with PBS containing 0.1% Triton
X-100 and incubated for 15min with four drops of Image-IT Fx signal enhancer
(Invitrogen). After three washes with PBS containing 0.1% Triton X-100, the
cells were stained for 1 hr with Cy2-conjugated anti-human and Texas Red-
conjugated anti-rabbit antibodies (Jackson ImmunoResearch). Cells were
washed three times with PBS containing 0.1% Triton X-100, rinsed twice
with water, and mounted with ProLong Gold containing DAPI (Invitrogen).
Images obtained with an Axioplan 2 light microscope (Carl Zeiss MicroImag-
ing) were recorded with a CoolSNAPHQ CCD camera (Photometrics).
Immunohistochemical Staining
Formalin-fixed, paraffin-embedded 3 mm sections were deparaffinized in
xylenes and rehydrated through a graded alcohol series. Antigen retrieval
was performed in Trilogy (Cell Marque) for Apu2.07 and Target high pH
Retrieval Solution (DAKO) for Apu3.A8. Endogenous peroxidase activity was
blockedwith KPL blocking solution (Kirkegaard and Perry Laboratories), which
was followed by an avidin/biotin block (Vector Labs), and then nonspecific
binding sites were blocked with PBS containing 10% goat serum and 3%
BSA. Staining was for 1 hr with 1 mg/ml Apu2.07 or 5 mg/ml Apu3.A8. Where
indicated, antibody was preincubated for 1 hr with a 10-fold excess of K48-
or K63-linked tetraubiquitin (Boston Biochem). Immunostaining was com-
pleted with biotinylated goat anti-human IgG (Vector Labs), ABC-HRP Elite
reagent (Vector Labs), and metal enhanced DAB substrate (Pierce). Sections
were counterstained with Myer’s Hematoxylin (Rowley Biochemical Institute).
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